Study Design and Setting
Nijmegen
DISEASES, MOVEMENT DISORDERS
We conducted a 5-week, randomized clinical trial, with a cross-over design for
the waiting-list control group, and a 15-week follow-up period after the
intervention. This mono-center study was conducted at the Center of Expertise
for Rare and Genetic Movement Disorders of the Radboud University Medical Center
(Nijmegen, The Netherlands), which is part of the European Reference Network for
Rare Neurological Diseases (ERN-RND). Ethical approval was obtained from the
Medical Ethical Committee Oost-Nederland, the Netherlands (2019-5602,
NL70295.091.19). The trial was registered on Clinicaltrials.gov (NCT04180098)
and the study protocol has previously been published.